NeuroRx Secures HK$ 750 M Capital for suicidal bipolar depression Therapy
Singapore, Oct. 29 -- NeuroRx, Inc, on 29 October 2019, announced that it has signed an agreement with GEM Global Yield LLC SCS ("GEM"), the New York-based private alternative investment group to provide the NeuroRx with up to HK$ 750 million over a 30-month term following a public listing of NeuroRx's common stock.
NeuroRx will use the funds to complete its phase 3 clinical trials and GMP manufacturing requirements in both the US and China for NRX-101, an FDA-designated Breakthrough Therapy in development for suicidal bipolar depression. The company further plans to initiate phase 2 clinical trials in the treatment of Suicidal Post-traumatic Stress Disorder (PTSD) under its Cooperative Research and Development Agreement with the US Depa...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.